Literature DB >> 11861842

Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished.

Victor W van Beusechem1, Jacques Grill, D C Jeroen Mastenbroek, Thomas J Wickham, Peter W Roelvink, Hidde J Haisma, Martine L M Lamfers, Clemens M F Dirven, Herbert M Pinedo, Winald R Gerritsen.   

Abstract

The application of adenoviral vectors in cancer gene therapy is hampered by low receptor expression on tumor cells and high receptor expression on normal epithelial cells. Targeting adenoviral vectors toward tumor cells may improve cancer gene therapy procedures by providing augmented tumor transduction and decreased toxicity to normal tissues. Targeting requires both the complete abolition of native tropism and the addition of a new specific binding ligand onto the viral capsid. Here we accomplished this by using doubly ablated adenoviral vectors, lacking coxsackievirus-adenovirus receptor and alpha(v) integrin binding capacities, together with bispecific single-chain antibodies targeted toward human epidermal growth factor receptor (EGFR) or the epithelial cell adhesion molecule. These vectors efficiently and selectively targeted both alternative receptors on the surface of human cancer cells. Targeted doubly ablated adenoviral vectors were also very efficient and specific with primary human tumor specimens. With primary glioma cell cultures, EGFR targeting augmented the median gene transfer efficiency of doubly ablated adenoviral vectors 123-fold. Moreover, EGFR-targeted doubly ablated vectors were selective for human brain tumors versus the surrounding normal brain tissue. They transduced organotypic glioma and meningioma spheroids with efficiencies similar to those of native adenoviral vectors, while exhibiting greater-than-10-fold-reduced background levels on normal brain explants from the same patients. As a result, EGFR-targeted doubly ablated adenoviral vectors had a 5- to 38-fold-improved tumor-to-normal brain targeting index compared to native vectors. Hence, single-chain targeted doubly ablated adenoviral vectors are promising tools for cancer gene therapy. They should provide an improved therapeutic index with efficient tumor transduction and effective protection of normal tissue.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861842      PMCID: PMC135966          DOI: 10.1128/jvi.76.6.2753-2762.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base.

Authors:  D A Einfeld; D E Brough; P W Roelvink; I Kovesdi; T J Wickham
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments.

Authors:  G A Huls; I A Heijnen; M E Cuomo; J C Koningsberger; L Wiegman; E Boel; A R van der Vuurst de Vries; S A Loyson; W Helfrich; G P van Berge Henegouwen; M van Meijer; J de Kruif; T Logtenberg
Journal:  Nat Biotechnol       Date:  1999-03       Impact factor: 54.908

3.  Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells.

Authors:  J Nalbantoglu; G Pari; G Karpati; P C Holland
Journal:  Hum Gene Ther       Date:  1999-04-10       Impact factor: 5.695

4.  Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways.

Authors:  J Doukas; D K Hoganson; M Ong; W Ying; D L Lacey; A Baird; G F Pierce; B A Sosnowski
Journal:  FASEB J       Date:  1999-08       Impact factor: 5.191

5.  Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae.

Authors:  P W Roelvink; G Mi Lee; D A Einfeld; I Kovesdi; T J Wickham
Journal:  Science       Date:  1999-11-19       Impact factor: 47.728

6.  Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice.

Authors:  H Romanczuk; C E Galer; J Zabner; G Barsomian; S C Wadsworth; C R O'Riordan
Journal:  Hum Gene Ther       Date:  1999-11-01       Impact factor: 5.695

7.  Enhancement of adenovirus-mediated gene delivery by use of an oligopeptide with dual binding specificity.

Authors:  S S Hong; A Galaup; R Peytavi; N Chazal; P Boulanger
Journal:  Hum Gene Ther       Date:  1999-11-01       Impact factor: 5.695

8.  Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM.

Authors:  H J Haisma; H M Pinedo; A Rijswijk; I der Meulen-Muileman; B A Sosnowski; W Ying; V W Beusechem; B W Tillman; W R Gerritsen; D T Curiel
Journal:  Gene Ther       Date:  1999-08       Impact factor: 5.250

9.  Collagens, integrins and the mesenchymal drift in glioblastomas: a comparison of biopsy specimens, spheroid and early monolayer cultures.

Authors:  W Paulus; C Huettner; J C Tonn
Journal:  Int J Cancer       Date:  1994-09-15       Impact factor: 7.396

10.  Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR.

Authors:  I Kirby; E Davison; A J Beavil; C P Soh; T J Wickham; P W Roelvink; I Kovesdi; B J Sutton; G Santis
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

View more
  21 in total

1.  Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells.

Authors:  Marianela Candolfi; James F Curtin; Wei-Dong Xiong; Kurt M Kroeger; Chunyan Liu; Altan Rentsendorj; Hasmik Agadjanian; Lali Medina-Kauwe; Donna Palmer; Philip Ng; Pedro R Lowenstein; Maria G Castro
Journal:  Mol Ther       Date:  2006-06-23       Impact factor: 11.454

2.  Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.

Authors:  L Pereboeva; S Komarova; J Roth; S Ponnazhagan; D T Curiel
Journal:  Gene Ther       Date:  2007-01-25       Impact factor: 5.250

3.  Viral nanoparticles as macromolecular devices for new therapeutic and pharmaceutical approaches.

Authors:  Simone Grasso; Luca Santi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-07-06

Review 4.  Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma.

Authors:  Yi-Gang Wang; Pan-Pan Huang; Rong Zhang; Bu-Yun Ma; Xiu-Mei Zhou; Yan-Fang Sun
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 5.  Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.

Authors:  Zineb Belcaid; Martine L M Lamfers; Victor W van Beusechem; Rob C Hoeben
Journal:  Hum Gene Ther       Date:  2014-09-17       Impact factor: 5.695

Review 6.  Cancer stem cells: the final frontier for glioma virotherapy.

Authors:  Mahua Dey; Ilya V Ulasov; Matthew A Tyler; Adam M Sonabend; Maciej S Lesniak
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

7.  Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer.

Authors:  Chunyan Liu; Yonggang Zhang; Minzhi Maggie Liu; Haoming Zhou; Wasim Chowdhury; Shawn E Lupold; Ted L Deweese; Ronald Rodriguez
Journal:  Int J Radiat Biol       Date:  2010-03       Impact factor: 2.694

Review 8.  Adenoviral virotherapy for malignant brain tumors.

Authors:  Suvobroto Nandi; Maciej S Lesniak
Journal:  Expert Opin Biol Ther       Date:  2009-06       Impact factor: 4.388

Review 9.  Virotherapy against malignant glioma stem cells.

Authors:  Mahua Dey; Ilya V Ulasov; Maciej S Lesniak
Journal:  Cancer Lett       Date:  2009-07-29       Impact factor: 8.679

10.  Herpes simplex virus type 1 preferentially targets human colon carcinoma: role of extracellular matrix.

Authors:  Dror Kolodkin-Gal; Gideon Zamir; Yair Edden; Eli Pikarsky; Alon Pikarsky; Hillel Haim; Yosef S Haviv; Amos Panet
Journal:  J Virol       Date:  2007-10-31       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.